HFB-101110

N/A

Report date: 2022/05/10 11:38:36

Base Information

Drug NameHFB-101110
Drug Alias NameHFB101110
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsC-C chemokine receptor type 8 inhibitorsT lymphocytes stimulants
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHiFiBiO Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesFibrogen IncHiFiBiO Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A